On Aug. 20, 2026, the FDA cleared PrecivityAD2 for adults age 40 and older with signs or symptoms of cognitive impairment, NeurologyLive reported in the FDA clearance report. PrecivityAD2 is a blood test that measures Alzheimer-related proteins and reports an Amyloid Probability Score 2.
Families facing possible younger-onset disease can bring focused questions about eligibility, meaning of results, and next steps. Younger-onset concerns often involve work, parenting, and family planning. Symptoms at ages 40 to 64 can also come from sleep disorders, depression, thyroid disease, or medication effects. A structured clinical evaluation helps separate those causes from Alzheimer pathology.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- What does the test measure?
- How accurate is it in symptomatic adults?
- Why is clinical evaluation still required?
- Which questions should families bring?
What does the test measure?
The test uses high-resolution mass spectrometry on a blood sample. It measures the plasma amyloid-beta 42/40 ratio, a balance of two amyloid fragments, and percent p-tau217, the share of tau carrying a disease-linked phosphate mark. C2N combines both markers into one score.
The score is reported as negative, positive, or intermediate likely-positive. Negative suggests a lower likelihood of brain amyloid. Positive suggests a higher likelihood, while intermediate gives no firm answer and needs further workup.
How accurate is it in symptomatic adults?
In C2N's 1,142-person symptomatic validation cohort, results were checked against amyloid PET or spinal fluid testing. A positive result had 97.6% positive predictive value, and a negative result had 93.1% negative predictive value. About 17.3% of results fell in the intermediate band, where positive predictive value was only 77.3%.
A separate 1,213-patient prospective study, published in JAMA in 2024, found diagnostic accuracy of about 88%-92% across primary and specialty care, according to the prospective JAMA study. Discrimination was very high, with area under the curve about 0.96-0.97. The blood score outperformed clinician evaluation without biomarkers.
Why is clinical evaluation still required?
The cleared use is narrow. It covers symptomatic adults undergoing evaluation for Alzheimer or other cognitive decline. It does not cover screening without symptoms and does not give a stand-alone diagnosis.
The Alzheimer's Association guideline for blood biomarkers, released July 29, 2025, sets a triage role for qualifying tests in specialty care, described in the Association's guideline release. Under that approach, a negative result largely argues against Alzheimer pathology. A positive result still calls for confirmation with spinal fluid testing or amyloid PET.
Which questions should families bring?
C2N said the FDA-cleared version was expected later in 2026 while its laboratory-developed test remained available. Families should therefore ask which version the clinic offers and how the clinic uses each result.
Clear answers reduce surprise bills, repeat draws, and delays in referrals. Bring a symptom timeline, medication list, sleep and mood history, and a family member who observes daily function. Ask for the follow-up plan in writing, including who orders confirmatory testing and when to return.
- Is this evaluation for current cognitive symptoms, not routine screening?
- Which test version will you order, and where will the sample be analyzed?
- What will a negative, positive, or intermediate likely-positive result change next?
- Will a positive result require spinal fluid testing or amyloid PET for confirmation?
- Could kidney disease, medications, or other conditions affect my result?
You Might Also Like
- Subjective Cognitive Decline Data for Public Health Action in 2026: What the News Means for Adults Over 65
- UAS-CLEAR Dementia Care Research Data Priorities in 2026: Questions Spouses and Partners Can Ask About the Research
- The Long-Term Care Data Cooperative and Dementia Research in 2026: Questions Spouses and Partners Can Ask About the Research





